PI3K, P38 and JAK/STAT Signalling in Bronchial Tissue from Patients with Asthma Following Allergen Challenge

Overview

Journal Biomark Res

Publisher Biomed Central

Date 2018 Apr 14

PMID 29651336

Citations 13

Authors

Thomas Southworth

Sarah Mason

Alan Bell

Isabel Ramis

Marta Calbet

Anna Domenech

Neus Prats

Montserrat Miralpeix

Dave Singh

Affiliations

Soon will be listed here.

Abstract

Background: Inhaled allergen challenges are often used to evaluate novel asthma treatments in early phase clinical trials. Current novel therapeutic targets in asthma include phosphoinositide 3-kinases (PI3K) delta and gamma, p38 mitogen-activated protein kinase (p38) and Janus kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling pathways. The activation of these pathways following allergen exposure in atopic asthma patients it is not known.

Methods: We collected bronchial biopsies from 11 atopic asthma patients at baseline and after allergen challenge to investigate biomarkers of PI3K, p38 MAPK and JAK/STAT activation by immunohistochemistry. Cell counts and levels of eosinophil cationic protein and interleukin-5 were also assessed in sputum and bronchoalvelar lavage.

Results: Biopsies collected post-allergen had an increased percentage of epithelial cells expressing phospho-p38 (17.5 vs 25.6%, = 0.04), and increased numbers of sub-epithelial cells expressing phospho-STAT5 (122.2 vs 540.6 cells/mm, = 0.01) and the PI3K marker phospho-ribosomal protein S6 (180.7 vs 777.3 cells/mm = 0.005). Type 2 inflammation was increased in the airways post allergen, with elevated levels of eosinophils, interleukin-5 and eosinophil cationic protein.

Conclusions: Future clinical trials of novel kinase inhibitors could use the allergen challenge model in proof of concept studies, while employing these biomarkers to investigate pharmacological inhibition in the lungs.

Citing Articles

Comprehensive landscape-style investigation of the molecular mechanism of acupuncture at ST36 single acupoint on different systemic diseases.

Fan X, Liu Y, Li S, Yang Y, Zhao Y, Li W Heliyon. 2024; 10(4):e26270.

PMID: 38375243 PMC: 10875596. DOI: 10.1016/j.heliyon.2024.e26270.

Protective Effects of Aqueous Extract against OVA-Induced Airway Hyperresponsiveness and Inflammation in Asthmatic Mice.

Yang Y, Lai Q, Wang C, Zhou G Evid Based Complement Alternat Med. 2022; 2022:7609785.

PMID: 36408342 PMC: 9674414. DOI: 10.1155/2022/7609785.

Emerging Roles of Non-Coding RNAs in Childhood Asthma.

Liang J, Liu X, Chen X, Song X, Li W, Huang Y Front Pharmacol. 2022; 13:856104.

PMID: 35656293 PMC: 9152219. DOI: 10.3389/fphar.2022.856104.

A Practical Strategy for Exploring the Pharmacological Mechanism of Luteolin Against COVID-19/Asthma Comorbidity: Findings of System Pharmacology and Bioinformatics Analysis.

Xie Y, Peng C, Su Z, Huang H, Liu X, Zhan S Front Immunol. 2022; 12:769011.

PMID: 35069542 PMC: 8777084. DOI: 10.3389/fimmu.2021.769011.

SB203580-A Potent p38 MAPK Inhibitor Reduces the Profibrotic Bronchial Fibroblasts Transition Associated with Asthma.

Paw M, Wnuk D, Nit K, Bobis-Wozowicz S, Szychowski R, Slusarczyk A Int J Mol Sci. 2021; 22(23).

PMID: 34884593 PMC: 8657816. DOI: 10.3390/ijms222312790.

References

Meyuhas O . Ribosomal Protein S6 Phosphorylation: Four Decades of Research. Int Rev Cell Mol Biol. 2015; 320:41-73. DOI: 10.1016/bs.ircmb.2015.07.006. View

Khan A, Southworth T, Worsley S, Sriskantharajah S, Amour A, Hessel E . An investigation of the anti-inflammatory effects and a potential biomarker of PI3Kδ inhibition in COPD T cells. Clin Exp Pharmacol Physiol. 2017; 44(9):932-940. DOI: 10.1111/1440-1681.12784. View

Brusselle G, Maes T, Bracke K . Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013; 19(8):977-9. DOI: 10.1038/nm.3300. View

Singh D, Leaker B, Boyce M, Nandeuil M, Collarini S, Mariotti F . A novel inhaled phosphodiesterase 4 inhibitor (CHF6001) reduces the allergen challenge response in asthmatic patients. Pulm Pharmacol Ther. 2016; 40:1-6. DOI: 10.1016/j.pupt.2016.06.011. View

Peters S . Asthma phenotypes: nonallergic (intrinsic) asthma. J Allergy Clin Immunol Pract. 2014; 2(6):650-2. DOI: 10.1016/j.jaip.2014.09.006. View

Lin C, Hong Y, Kao S . Aeroallergen Der p 2 induces apoptosis of bronchial epithelial BEAS-2B cells via activation of both intrinsic and extrinsic pathway. Cell Biosci. 2015; 5:71. PMC: 4687151. DOI: 10.1186/s13578-015-0063-5. View

Hackett T, Singhera G, Shaheen F, Hayden P, Jackson G, Hegele R . Intrinsic phenotypic differences of asthmatic epithelium and its inflammatory responses to respiratory syncytial virus and air pollution. Am J Respir Cell Mol Biol. 2011; 45(5):1090-100. DOI: 10.1165/rcmb.2011-0031OC. View

Southworth T, Metryka A, Lea S, Farrow S, Plumb J, Singh D . IFN-γ synergistically enhances LPS signalling in alveolar macrophages from COPD patients and controls by corticosteroid-resistant STAT1 activation. Br J Pharmacol. 2012; 166(7):2070-83. PMC: 3402772. DOI: 10.1111/j.1476-5381.2012.01907.x. View

Aalbers R, Vogelmeier C, Kuna P . Achieving asthma control with ICS/LABA: A review of strategies for asthma management and prevention. Respir Med. 2015; 111:1-7. DOI: 10.1016/j.rmed.2015.11.002. View

10.

Khorasanizadeh M, Eskian M, Gelfand E, Rezaei N . Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther. 2017; 174:112-126. DOI: 10.1016/j.pharmthera.2017.02.024. View

11.

Liu W, Liang Q, Balzar S, Wenzel S, Gorska M, Alam R . Cell-specific activation profile of extracellular signal-regulated kinase 1/2, Jun N-terminal kinase, and p38 mitogen-activated protein kinases in asthmatic airways. J Allergy Clin Immunol. 2008; 121(4):893-902.e2. DOI: 10.1016/j.jaci.2008.02.004. View

12.

Kubota H, Noguchi R, Toyoshima Y, Ozaki Y, Uda S, Watanabe K . Temporal coding of insulin action through multiplexing of the AKT pathway. Mol Cell. 2012; 46(6):820-32. DOI: 10.1016/j.molcel.2012.04.018. View

13.

Bell B, Kitajima M, Larson R, Stoklasek T, Dang K, Sakamoto K . The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. Nat Immunol. 2013; 14(4):364-71. PMC: 4161284. DOI: 10.1038/ni.2541. View

14.

Ross J, Nagy Z, Cheng H, Stepkowski S, Kirken R . Regulation of T cell homeostasis by JAKs and STATs. Arch Immunol Ther Exp (Warsz). 2007; 55(4):231-45. DOI: 10.1007/s00005-007-0030-x. View

15.

Cosmi L, Liotta F, Annunziato F . Th17 regulating lower airway disease. Curr Opin Allergy Clin Immunol. 2015; 16(1):1-6. DOI: 10.1097/ACI.0000000000000227. View

16.

Southworth T, Plumb J, Gupta V, Pearson J, Ramis I, Lehner M . Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients. Respir Res. 2016; 17(1):124. PMC: 5051065. DOI: 10.1186/s12931-016-0436-2. View

17.

Kolsum U, Ravi A, Hitchen P, Maddi S, Southworth T, Singh D . Clinical characteristics of eosinophilic COPD versus COPD patients with a history of asthma. Respir Res. 2017; 18(1):73. PMC: 5405469. DOI: 10.1186/s12931-017-0559-0. View

18.

Boomer J, Parulekar A, Patterson B, Yin-DeClue H, Deppong C, Crockford S . A detailed phenotypic analysis of immune cell populations in the bronchoalveolar lavage fluid of atopic asthmatics after segmental allergen challenge. Allergy Asthma Clin Immunol. 2013; 9(1):37. PMC: 3848528. DOI: 10.1186/1710-1492-9-37. View

19.

Dhawale V, Amara V, Karpe P, Malek V, Patel D, Tikoo K . Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model. Toxicol Appl Pharmacol. 2016; 306:17-26. DOI: 10.1016/j.taap.2016.06.026. View

20.

Lee W, Southworth T, Singh D . Different inhaled allergen challenge models give reproducible results. Pulm Pharmacol Ther. 2015; 33:57-8. DOI: 10.1016/j.pupt.2015.06.005. View